AMSBIO has expanded its range of primary human cancer cells sourced from a wide variety of tissue types. The cells allow the study of cancer in a more in vivo–like fashion. Many scientists acknowledge that using immortalized cell lines as surrogates offers only a poor reflection of the diverse profiles of real cancer tumors. The company explains that it created the new cells to address the need for new in vitro cancer models, utilizing primary tumor cells that more closely reproduce the in vivo cancer microenvironment, and claims that its donor-derived primary tumor cells offer a more in vivo–like model.